Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 12/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14940191 | 0.96 | RAPGEF4 (0.54) | RAPGEF4NFKB1CRHR1 | |
| SCHEMBL1181478 | 0.82 | RAPGEF4 (0.52) | RAPGEF4CRHR1 | |
| SCHEMBL1181728 | 0.81 | CYP2C9 (0.48) | RAPGEF4NFKB1APPNPC1POLB | |
| SCHEMBL14940258 | 0.81 | NFKB1 (0.45) | RAPGEF4NFKB1CRHR1APPNPC1 | |
| SCHEMBL14940406 | 0.80 | RAPGEF4 (0.54) | RAPGEF4CRHR1NPC1 | |
| SCHEMBL5447308 | 0.79 | RAPGEF4 (0.48) | RAPGEF4CRHR1 | |
| SCHEMBL14347189 | 0.79 | RAPGEF4 (0.58) | RAPGEF4CRHR1NPC1 | |
| SCHEMBL16206659 | 0.78 | CRHR1 (0.54) | RAPGEF4CRHR1 | |
| SCHEMBL1181589 | 0.77 | NFKB1 (0.53) | NFKB1APPNPC1POLB | |
| SCHEMBL14939965 | 0.76 | NFKB1 (0.56) | NFKB1APPNPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323488-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | UNIVERSITEIT ANTWERPEN (BE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323488-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | UNIVERSITEIT ANTWERPEN (BE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323488-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | UNIVERSITEIT ANTWERPEN (BE) | 2014-10-30 | — | — | US | disclosed |
| EP-2776410-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | Universiteit Antwerpen (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068551-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | UNIVERSITEIT ANTWERPEN (BE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323488-A1 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | TBC1D15, TBC1D5, DHFR | RAPGEF4 4150/4885NFKB1 559/4885CRHR1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.